The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase α leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5507-5517

  Al Saffar, Nada M S ^a   Jackson, L Elizabeth ^a   Raynaud, Florence I ^b   Clarke, Paul A ^b   De Molina, Ana Ramírez ^c   Lacal, Juan C ^c   Workman, Paul ^b   Leach, Martin O ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; CHOLINE KINASE; CHOLINE KINASE ALPHA; DOCETAXEL; FATTY ACID SYNTHASE; GLYCEROPHOSPHORYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; CELL LINE, TUMOR; CHOLINE; CHOLINE KINASE; DOWN-REGULATION; FURANS; HCT116 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMBRANE PROTEINS; PHOSPHORYLCHOLINE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; PYRIDINES; PYRIMIDINES;

EID: 77954358936     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4476     Document Type: Article

References (49)

1. Gadian DG. The information available from NMR. NMR and its applications to living systems. 2 ed. New York: Oxford University Press Inc; 1995, p. 29-64.
2. Payne GS, Leach MO. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol 2006;79 Spec No 1:S16-26.
3. Shah N, Sattar A, Benanti M, Hollander S, Cheuck L. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc 2006;106:23-7. (Pubitemid 43161596)
4. Negendank W. Studies of human tumours by MRS: a review. NMR Biomed 1992;5:303-24.
5. Smith TAD, Bush C, Jameson C, et al. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed 1993;6:318-23.
6. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4.
7. Backshall A, Alferez D, Teichert F, et al. Detection of metabolic alterations in non-tumor gastrointestinal tissue of the Apc(Min/+) mouse by (1)H MAS NMR spectroscopy. J Proteome Res 2009;8:1423-30.
8. Chan EC, Koh PK, Mal M, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 2009;8: 352-61.
9. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700. (Pubitemid 44764211)
10. Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO. Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br J Cancer 2010;102:1-7.
11. Workman P, Aboagye EO, Chung YL, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesistesting clinical trials of innovative therapies. J Natl Cancer Inst 2006; 98:580-98. (Pubitemid 43904842)
12. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19. (Pubitemid 44100518)
13. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase P110a inhibitors. Bioorg Med Chem 2006; 14:6847-58.
14. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem Lett 2007;17: 2438-42.
15. Hayakawa M, Kaizawa H, Kawaguchi K, et al. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2007;15: 403-12.
16. Hayakawa M, Kawaguchi K, Kaizawa H, et al. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2007;15: 5837-44.
17. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010;70:2146-57.
18. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9: 341-9.
19. Guillard S, Clarke PA, Te-Poele R, et al. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 2009;8:443-53.
20. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-50.
21. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
22. Beloueche-Babari M, Jackson LE, Al Saffar NMS, et al. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther 2006;5:187-96.
23. Chung YL, Troy H, Banerji U, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17- demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003;95: 1624-33.
24. Al-Saffar NS, Troy H, Ramírez de Molina A, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in Human Carcinoma models. Cancer Res 2006;66:427-34.
25. Gallego-Ortega D, Ramírez de Molina A, Gutierrez R, et al. Generation and characterization of monoclonal antibodies against choline kinase α and their potential use as diagnostic tools in cancer. Int J Oncol 2006;29:335-40.
26. Tyagi RK, Azrad A, Degani H, Salomon Y. Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn Reson Med 1996;35:194-200.
27. Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays 2002;24: 65-71.
28. Mackler NJ, Pienta KJ. Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2005;2:92-100.
29. Ramírez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and P13K. Oncogene 2002;21:937-46. (Pubitemid 34146307)
30. Wang HQ, Altomare DA, Skele KL, et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005;24:3574-82.
31. Porstmann T, Griffiths B, Chung YL, et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005;24:6465-81. (Pubitemid 41486630)
32. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008;8:393-412.
33. Beloueche-Babari M, Jackson LE, Al Saffar NMS, Workman P, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res 2005;65:3356-63. (Pubitemid 40524620)
34. Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen SM. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther 2008;7:2556-65.
35. Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1α inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed 2005;18:430-9. (Pubitemid 41646184)
36. Beloueche-Babari M, Peak JC, Jackson LE, Tiet MY, Leach MO, Eccles SA. Changes in choline metabolism as potential biomarkers of phospholipase C{γ}1 inhibition in human prostate cancer cells. Mol Cancer Ther 2009;8:1305-11.
37. Chung YL, Troy H, Kristeleit R, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 2008;10:303-13.
38. Sankaranarayanapillai M, Tong WP, Yuan Q, et al. Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method. Mol Imaging 2008;7:92-100.
39. Murphy PS, Viviers L, Abson C, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004;90:781-6.
40. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12: 413-39.
41. Lacal JC, Moscat J, Aaronson SA. Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature 1987;330: 269-72.
42. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2002; 84:691-6.
43. Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008;8:224-36.
44. Porstmann T, Santos CR, Lewis C, Griffiths B, Schulze A. A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size. Biochem Soc Trans 2009;37:278-83.
45. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6.
46. Spadaro F, Ramoni C, Mezzanzanica D, et al. Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res 2008;68:6541-9.
47. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 2007; 120:1721-30.
48. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007;17: 666-81.
49. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem 2002;277: 33895-900.